BRAF and cancer: In this respect, although the clinical outcome of RAS/BRAF WT mCRC has been improved in recent years for the integration of EGFR agents in the continuum of care, the antitumor efficacy of these drugs is transient and EGFR inhibitor-acquired cancer resistance occurs [2, 5, 25].